Products - Children and teenagers | Topic

Showing 23 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 August 2026
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
3 September 2026
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
3 September 2026
Gender Incongruence Services for Children and Young People
Status:
In development
Expected publication date:
2 December 2026
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 February 2027
Multidisciplinary care of children and young people with achondroplasia
Status:
In development
Programme:
NICE review
Expected publication date:
29 April 2926
School-based interventions: physical and mental health and wellbeing promotion
Status:
In development
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [TSID10632]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over [TSID12091]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epilepsies in children, young people and adults
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Children and teenagers Products

Filter

Product type

Guidance programme

Advice programme

Status
1 selected

New and updated

Showing 23 products

12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]

Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]

Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

Gender Incongruence Services for Children and Young People

Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]

Multidisciplinary care of children and young people with achondroplasia

School-based interventions: physical and mental health and wellbeing promotion

Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

Omburtamab for treating relapsed neuroblastoma [ID1664]

Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]

Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

Vosoritide for treating achondroplasia in people 4 months and over [ID6488]

Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [TSID10632]

Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over [TSID12091]

Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]

Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]

Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]

Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]

Epilepsies in children, young people and adults

Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]

Children and teenagers Products

Filter

Product type

Guidance programme

Advice programme

Status1 selected

New and updated

Showing 23 products

Status
1 selected